We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.85 | 8.70 | 9.00 | 8.85 | 8.85 | 8.85 | 1,881,932 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.43 | 15.4M |
From May 2019 to May 2024
TIDMSBTX
RNS Number : 5117X
SkinBioTherapeutics PLC
19 December 2019
SkinBioTherapeutics plc
(the "Company")
Result of AGM
SkinBioTherapeutics plc (AIM: SBTX), announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468 Stuart Ashman, CEO 2760 Doug Quinn, CFO Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 Adviser) 0880 Tony Rawlinson / Sandy Jamieson SP Angel Corporate Finance (Joint Broker) Tel: +44 (0) 20 3470 Vadim Alexandre / Abigail Wayne 0470 Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657 Andy Thacker / Zoe Alexander 0050 Instinctif Partners Tel: +44 (0) 20 7457 Melanie Toyne-Sewell / Phil Marriage 2020 / Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit: www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGCKCDQDBDDABD
(END) Dow Jones Newswires
December 19, 2019 06:47 ET (11:47 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
